• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 3rd August 2010

Limits to Using QALYs in Cancer

QALY measures have become important tools in valuing health interventions so that resource allocations can be made. Current methods, however, may not adequately capture QALYs for cancer patients, particularly in the last years of life. This post reviews the issues…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

QALY measures have become important tools in valuing health interventions so that resource allocations can be made. Current methods, however, may not adequately capture QALYs for cancer patients, particularly in the last years of life. This post reviews the issues and suggests next steps.

A quality-adjusted life year, or QALY, is a year of life adjusted for its quality or its value for the individual.  A year in perfect health would be equal to 1 QALY; the value for less than perfect health would decline as health declines.  QALYs are used to assess the value of medical interventions and may be used in decisions about allocating health care resources.  In the UK for example, NICE uses QALYs to ‘compare different drugs and measure their clinical effectiveness’[1]; NICE recommendations determine whether health care interventions are covered under the NHS.  Clearly, then, ensuring that QALYs accurately reflect reality is crucial.

Koonal Shah, a health economist at the OHE, has been part of a team[2] researching how well QALYs assess cancer patients’ health gains from treatment.  He presented key findings in June 2010 at the annual conference of Health Technology Assessment International.

QALYs are calculated by multiplying the duration of each health state experienced by patients by the value ascribed to that state.  Health states are measured using instruments such as the EQ-5D; valuations are based on the preferences of a sample of the general population.

According to Mr Shah, existing methods for constructing QALYs may be deficient for cancer patients in three respects: descriptions of health state, valuation of health state and the source of values upon which measures are based.

Existing measures of health are either not sensitive enough or not attuned to cancer patients’ actual preferences.  For example, evidence suggests that the EQ-5D instrument does not capture the small changes in health that often are very important to cancer patients.

Valuation of health states for cancer patients using traditional methods also encounters problems.  For example, the time trade-off (TTO) method assumes that the rate at which people are willing to trade life expectancy for  improvements in quality of life is the same under all circumstances.  Research has shown, however, that (1) severely ill patients often are willing to sacrifice more life expectancy for smaller gains in health-related quality of life and (2) patients with less than one year to live are often unwilling to trade any time.

Whose values form the basis of health state valuations also matters.  NICE recommends that valuations of EQ-5D health states be based on the preferences of the general public. Descriptions of health states using EQ-5D, however, are too general to provide the public with a complete depiction of the patient experience. The public also tends to focus on the negative aspects of ill health, missing the fact that some areas of life are not seriously affected.  Finally, a discrepancy exists between the way patients actually adapt to ill health and healthy individuals’ perceptions of their own abilities to adapt. Overall, using the general public to value health states may overvalue interventions aimed at achieving perfect health and undervalue those aimed at prolonging life or achieving small improvements in HRQL.

Mr Shah proposes three possible ways forward, given these concerns.  First, improve descriptions by adding dimensions or levels to EQ-5D and/or develop cancer-specific instruments.  Second, develop the TTO approach so that it captures the nuances of the relationship between remaining life and quality of life.  And, third, make health state descriptions more comprehensive and/or realistic to achieve better-informed valuations.

Download Garau, M., Shah, K.K., Mason, A.R., Wang, Q., Towse, A. and Drummond, M.F. (2010) Using QALYs in cancer:  Review of the methodological limitations. Research Paper. London: Office of Health Economics.

See also: Garau, M., Shah, K.K., Mason, A.R., Wang, Q., Towse, A. and Drummond, M.F. (2011) Using QALYs in cancer:  A review of the methodological limitations.  Pharmacoeconomics. 29(8), 673-685.  


[1]http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp [2] The team also includes colleagues at OHE and Anne Masson and Professor Mike Drummond of the University of York’s Centre for Health Economics.

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • NICE

Related News

  • News
  • December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!